Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine + cyclophosphamide + rituximab followed by rituximab maintenance in advanced untreated indolent non-follicular B-cell NHL
2004-002733-39Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, fludarabine and cyclophosphamide in low-grade B-cell lymphoma, sponsored by Roche. Started Feb 2007; status: completed.
02
Drugs
rituximabfludarabinecyclophosphamide
03
Conditions
low-grade B-cell lymphoma
Beyond the preview
Go deeper on 2004-002733-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002733-39.